Long-Term Persisting SARS-CoV-2 RNA and Pathological Findings: Lessons Learnt From a Series of 35 COVID-19 Autopsies.
COVID-19
SARS-CoV-2 RNA PCR
autopsy
histopathology
long-COVID
postmortal swabs
pulmonary superinfections
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
09
2021
accepted:
04
01
2022
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Long-term sequelae of coronavirus disease 2019 (COVID-19), including the interaction between persisting viral-RNA and specific tissue involvement, pose a challenging issue. In this study, we addressed the chronological correlation (after first clinical diagnosis and postmortem) between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and organ involvement. The presence of postmortem SARS-CoV-2 RNA from 35 complete COVID-19 autopsies was correlated with the time interval between the first diagnosis of COVID-19 and death and with its relationship to morphologic findings. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be evident up to 40 days after the first diagnosis and can persist to 94 hours after death. Postmortem SARS-CoV-2 RNA was mostly positive in lungs (70%) and trachea (69%), but all investigated organs were positive with variable frequency. Late-stage tissue damage was evident up to 65 days after initial diagnosis in several organs. Positivity for SARS-CoV-2 RNA in pulmonary swabs correlated with diffuse alveolar damage ( Our data provide evidence not only of long-term postmortem persisting SARS-CoV-2 RNA but also of tissue damage several weeks after the first diagnosis of SARS-CoV-2 infection. Additional conditions, such as concomitant bacterial pulmonary superinfection, lung aspergillosis, thromboembolic phenomena, and hemorrhages can further worsen tissue damage.
Sections du résumé
BACKGROUND
BACKGROUND
Long-term sequelae of coronavirus disease 2019 (COVID-19), including the interaction between persisting viral-RNA and specific tissue involvement, pose a challenging issue. In this study, we addressed the chronological correlation (after first clinical diagnosis and postmortem) between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and organ involvement.
METHODS
METHODS
The presence of postmortem SARS-CoV-2 RNA from 35 complete COVID-19 autopsies was correlated with the time interval between the first diagnosis of COVID-19 and death and with its relationship to morphologic findings.
RESULTS
RESULTS
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA can be evident up to 40 days after the first diagnosis and can persist to 94 hours after death. Postmortem SARS-CoV-2 RNA was mostly positive in lungs (70%) and trachea (69%), but all investigated organs were positive with variable frequency. Late-stage tissue damage was evident up to 65 days after initial diagnosis in several organs. Positivity for SARS-CoV-2 RNA in pulmonary swabs correlated with diffuse alveolar damage (
CONCLUSIONS
CONCLUSIONS
Our data provide evidence not only of long-term postmortem persisting SARS-CoV-2 RNA but also of tissue damage several weeks after the first diagnosis of SARS-CoV-2 infection. Additional conditions, such as concomitant bacterial pulmonary superinfection, lung aspergillosis, thromboembolic phenomena, and hemorrhages can further worsen tissue damage.
Identifiants
pubmed: 35223894
doi: 10.3389/fmed.2022.778489
pmc: PMC8865372
doi:
Types de publication
Journal Article
Langues
eng
Pagination
778489Informations de copyright
Copyright © 2022 Maccio, Zinkernagel, Schuepbach, Probst-Mueller, Frontzek, Brugger, Hofmaenner, Moch and Varga.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Eur J Radiol. 2020 Dec;133:109393
pubmed: 33161199
Ann Clin Transl Neurol. 2020 Nov;7(11):2221-2230
pubmed: 33016619
Int J Infect Dis. 2021 Apr;105:374-376
pubmed: 33684560
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Clin Microbiol Infect. 2021 Mar;27(3):469.e9-469.e15
pubmed: 33068757
Am J Pathol. 2021 Aug;191(8):1374-1384
pubmed: 34033751
Radiology. 2020 Nov;297(2):E242-E251
pubmed: 32544034
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Forensic Sci Int. 2021 Feb;319:110653
pubmed: 33360242
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Cell Mol Immunol. 2021 May;18(5):1305-1307
pubmed: 33742186
Trends Immunol. 2020 Dec;41(12):1083-1099
pubmed: 33153908
Cells. 2021 Mar 10;10(3):
pubmed: 33801959
Stroke. 2017 Apr;48(4):1085-1087
pubmed: 28235962
Mod Pathol. 2021 Sep;34(9):1614-1633
pubmed: 34031537
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Occup Environ Med. 2021 Mar 1;63(3):e159-e162
pubmed: 33405498
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Clin Infect Dis. 2021 Mar 1;72(5):905-906
pubmed: 32544219
Swiss Med Wkly. 2021 Aug 10;151:w20569
pubmed: 34375985
J Thromb Haemost. 2020 Sep;18(9):2110-2117
pubmed: 32608159
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
Int J Environ Res Public Health. 2021 Mar 05;18(5):
pubmed: 33807869
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Brain Pathol. 2020 Nov;30(6):1012-1016
pubmed: 32762083
J Immunol. 2020 Sep 15;205(6):1488-1495
pubmed: 32699160
Elife. 2021 Mar 30;10:
pubmed: 33781385
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
PLoS One. 2020 Jun 23;15(6):e0234765
pubmed: 32574165
Neuropathol Appl Neurobiol. 2021 Apr;47(3):454-459
pubmed: 33249605
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Blood Rev. 2021 Jan;45:100707
pubmed: 32425294
J Clin Pathol. 2021 Nov;74(11):752
pubmed: 33184063
J Clin Med. 2020 May 14;9(5):
pubmed: 32422983
AJNR Am J Neuroradiol. 2020 Nov;41(11):2001-2008
pubmed: 32819899
Diagn Histopathol (Oxf). 2021 Mar;27(3):103-107
pubmed: 33312230
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
Virchows Arch. 2021 Feb;478(2):343-353
pubmed: 32815036
Arch Pathol Lab Med. 2020 Nov 1;144(11):1298-1302
pubmed: 32589448
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Infect Dis. 2021 Jun 1;72(11):e921
pubmed: 32986798
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Signal Transduct Target Ther. 2020 Dec 4;5(1):283
pubmed: 33277466
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32404482
Am J Surg Pathol. 2021 May 1;45(5):587-603
pubmed: 33481385
Ocul Surf. 2021 Jan;19:322-329
pubmed: 33176215
Infect Control Hosp Epidemiol. 2021 Jan;42(1):84-88
pubmed: 32703320
Microorganisms. 2021 Apr 10;9(4):
pubmed: 33920259
Brain Behav Immun. 2020 Oct;89:543-554
pubmed: 32682993
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Pathol Res Pract. 2021 Jan;217:153305
pubmed: 33285423
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
J Infect Dis. 2021 Aug 2;224(3):389-394
pubmed: 33999152
Radiology. 2020 Dec;297(3):E313-E323
pubmed: 32677875
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
Cell Rep Med. 2021 Apr 20;2(4):100229
pubmed: 33748789
Aging Clin Exp Res. 2021 Jan;33(1):193-199
pubmed: 33345291